Delivery Format of Cognitive Behavioral Therapy Materials on Engagement and Outcomes: AI-Enabled App vs PDF Workbook

December 5, 2024 updated by: Limbic Limited

Comparison of Delivery Format of Cognitive Behavioral Therapy Materials on Engagement and Symptom Reduction: AI-Enabled App vs PDF Workbook

The goal of this clinical trial is to compare two different ways of delivering cognitive behavioral therapy (CBT) materials to people with symptoms of anxiety and depression. The main questions it aims to answer are:

  1. Do people using the app experience greater reductions in anxiety and depression symptoms compared to those using the workbook?
  2. Does the personalization offered by the app increase engagement with CBT materials compared to the workbook?

Participants will be given access to either the Limbic Care app or an equivalent PDF workbook and will be asked to engage with the materials for several days each week over a period of 6 weeks. Each week, participants will complete a survey about their anxiety and depression symptoms and report any new health issues and their experiences with the materials.

Study Overview

Status

Completed

Conditions

Detailed Description

Motivation

Homework is a crucial component of cognitive-behavioral therapy (CBT) as it allows patients to actively implement therapeutic techniques and skills outside of sessions, promoting long-term mental health improvements. However, patient engagement with CBT homework can be challenging due to a lack of motivation, forgetfulness, or a lack of personalization, which can hinder the overall effectiveness of the therapy and retention in a therapy program.

Design

This randomized controlled trial (RCT) aims to evaluate the efficacy, acceptability, and safety of an AI-enabled smartphone application (Limbic Care) compared to a standard digital workbook (PDF format) in delivering cognitive behavioral therapy (CBT) materials to individuals with clinically significant symptoms of anxiety and/or depression. The study will involve 500 participants, who will be randomly allocated in a 3:2 ratio to either the intervention group (Limbic Care app) or the control group (PDF workbook).

A large cohort (~2,000 participants) will initially be screened for inclusion and exclusion criteria. Eligible participants will be invited to participate in a baseline survey (capped at 550 to account for attrition and reach a target of 500 participants for the final data collection point). This survey will measure multiple validated symptom scales (e.g., for anxiety, depression, obsessive-compulsive disorder, health anxiety disorder) and gather subjective ratings on variables such as familiarity with CBT, previous experience with mental health apps, preferences for apps vs. PDF workbooks, medication status, and more.

After the baseline survey, participants will be randomly allocated to one of the two experimental arms and invited to download the app (intervention group) or to access the PDF workbook via a weblink (control group). Over a 6-week period, participants will be asked to engage with their assigned materials (app or workbook) for a specified number of days each week. Weekly surveys will measure changes in anxiety (GAD-7) and depression (PHQ-9) symptoms, as well as any new adverse health events. Additionally, engagement metrics such as time spent using the app or viewing workbook pages will be automatically recorded.

Outcome Measures

The primary outcomes are changes in GAD-7 and PHQ-9 scores from baseline to week 6, measured weekly. We will also use engagement (operationalised as the time spent with the materials, as well as the number of exercises interacted with) as a primary outcome, with the aim of investigating whether this is a mediating factor for any effect of material format (app vs workbook) on symptom reduction.

The secondary outcome is the incidence of adverse health events, to estimate and compare the safety of each material format.

Additional outcome measures include changes in the Work and Social Adjustment Scale (WSAS), self-reported satisfaction and acceptability, perceived utility and effectiveness, motivation to engage with the materials, and changes in sleep quality (measured by the Mini Sleep Questionnaire, MSQ).

Data Analysis

Data will be analyzed using appropriate statistical methods to compare the intervention and control groups. Primary and secondary outcomes will be analyzed using repeated measures ANOVA or mixed-effects models, adjusting for baseline scores and potential confounders. Subgroup analyses will be conducted to explore the effects of demographic variables on treatment outcomes.

Ethics and Safety

The study has been approved by the UCL research ethics committee and will be conducted in accordance with the Declaration of Helsinki. Participants' safety and confidentiality will be prioritized throughout the study. Adverse events will be closely monitored, and participants will have the option to withdraw from the study at any time without penalty.

Study Type

Interventional

Enrollment (Actual)

540

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Greater London
      • London, Greater London, United Kingdom, EC1V 2NX
        • Limbic Limited

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Has a personal smartphone with Internet access with an accepted operating system: iOS (any) or Android (10 or later)
  • Has a GAD-7 score >= 8 OR a PHQ-9 score >= 10 (indicating anxiety and/or depression symptoms above a clinical threshold, according to NHS Talking Therapies guidelines)
  • US resident
  • Fluent in English

Exclusion Criteria:

  • Currently undergoing mental health therapy
  • Changed psychotropic medication in the past 8 weeks (this includes starting/stopping medication or increasing/decreasing dosage)
  • Self-identify as being at risk of harming themselves or others
  • Have used the Limbic app before
  • Use recreational drugs more frequently than once per week
  • Consume >= 10 alcohol units per week

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AI-Enabled Mobile Application (Limbic Care)
Participants are given access to Limbic Care, a smartphone application that uses conversational AI to deliver cognitive behavioral therapy interventions and psychoeducation, provide support through active listening, and help answer questions about the therapeutic material.
Limbic Care is an AI-enabled smartphone application that delivers cognitive behavioral therapy (CBT) interventions and psychoeducation to users via an interactive, conversational interface using AI. Participants can choose from three "courses" (sleep, worry, and low mood) that sets the type of content they will see in the app. For each course, different interventions and psychoeducation material will appear in the "to do list" section of the app on a fixed schedule. The app also allows users to engage in open-ended conversation with the AI, which serves as an non-interventional, empathetic listener.
Active Comparator: Digital Workbook (PDF)
Participants are provided with a link to the digital workbook (in PDF format) that can be accessed via the Internet. The workbook contains cognitive behavioral therapy interventions and psychoeducation material.
The digital workbook in PDF format will be provided to participants via the Internet. Participants can choose from three workbooks that each focus on a different topic: sleep, worry, and low mood. Each workbook contains psychoeducation material and CBT intervention worksheets, consisting of text, images, and response boxes to write in (if printed out).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in GAD-7 (Anxiety)
Time Frame: Baseline to Week 6, and weekly (from Baseline to Week 6)
The GAD-7 (Generalized Anxiety Disorder-7) is a 7-item self-report questionnaire used to screen for and measure the severity of generalized anxiety disorder (GAD).
Baseline to Week 6, and weekly (from Baseline to Week 6)
Change in PHQ-9 (Depression)
Time Frame: Baseline to Week 6, and weekly (from Baseline to Week 6)
The PHQ-9 (Patient Health Questionnaire-9) is a 9-item self-report screening and diagnostic tool for depression.
Baseline to Week 6, and weekly (from Baseline to Week 6)
Therapy Completion
Time Frame: Summed across Week 1 to Week 6
Proportion of therapy content viewed (exercises in-app, or PDF pages viewed)
Summed across Week 1 to Week 6
Engagement Duration
Time Frame: Summed across Week 1 to Week 6
Time spent in the Limbic Care application (intervention) or viewing workbook pages (control).
Summed across Week 1 to Week 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Adverse Health Events
Time Frame: Summed across Week 1 to Week 6
Self-reported incidence of any adverse health events (physical or mental) experienced in the past week.
Summed across Week 1 to Week 6

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in WSAS (Wellbeing)
Time Frame: Baseline to Week 6, and weekly (from Baseline to Week 6)
The Work and Social Adjustment Scale (WSAS) is a 5-item self-report measure used to assess the degree of functional impairment attributable to an identified problem or disorder (for this study, participants were asked to consider their problems more generally).
Baseline to Week 6, and weekly (from Baseline to Week 6)
Change in MSQ (Sleep)
Time Frame: Baseline to Week 6, and weekly (from Baseline to Week 6)
The Mini Sleep Questionnaire (MSQ) is a 10-question self-report instrument designed to screen for excessive daytime sleepiness (EDS) and sleep disorders.
Baseline to Week 6, and weekly (from Baseline to Week 6)
Satisfaction and Acceptability
Time Frame: Weekly, from Week 1 to Week 6
Self-report ratings on Likert scales from 1 (worst) to 5 (best) for satisfaction and acceptability (Achievement, Motivation, Personalisation, Satisfaction, Structuredness).
Weekly, from Week 1 to Week 6
Utility and Effectiveness
Time Frame: Weekly, from Week 1 to Week 6
Self-report ratings on Likert scales from 1 (worst) to 5 (best) for usability and effectiveness (Effectiveness, Future Use, Learning, Understandability, Usefulness, Accessibility, and Ease of Use)
Weekly, from Week 1 to Week 6
Motivation
Time Frame: Weekly, from Week 1 to Week 6
Self-report ratings on Likert scales 1 (worst) to 5 (best) for how motivation (App Preference, Likelihood of Trying Therapy, and Trust in Wellbeing Apps that Use AI)
Weekly, from Week 1 to Week 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Max Rollwage, PhD, Limbic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 5, 2024

Primary Completion (Actual)

July 17, 2024

Study Completion (Actual)

July 17, 2024

Study Registration Dates

First Submitted

June 10, 2024

First Submitted That Met QC Criteria

June 10, 2024

First Posted (Actual)

June 14, 2024

Study Record Updates

Last Update Posted (Estimated)

December 6, 2024

Last Update Submitted That Met QC Criteria

December 5, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

IPD will not be shared with other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mental Health Issue

Clinical Trials on Limbic Care

Subscribe